Literature DB >> 22924606

The dynamic nature of type 1 cannabinoid receptor (CB(1) ) gene transcription.

R B Laprairie1, M E M Kelly, E M Denovan-Wright.   

Abstract

UNLABELLED: The type 1 cannabinoid receptor (CB(1) ) is an integral component of the endocannabinoid system that modulates several functions in the CNS and periphery. The majority of our knowledge of the endocannabinoid system involves ligand-receptor binding, mechanisms of signal transduction, and protein-protein interactions. In contrast, comparatively little is known about regulation of CB(1) gene expression. The levels and anatomical distribution of CB(1) mRNA and protein are developmental stage-specific and are dysregulated in several pathological conditions. Moreover, exposure to a variety of drugs, including cannabinoids themselves, alters CB(1) gene expression and mRNA levels. As such, alterations in CB(1) gene expression are likely to affect the optimal response to cannabinoid-based therapies, which are being developed to treat a growing number of conditions. Here, we will examine the regulation of CB(1) mRNA levels and the therapeutic potential inherent in manipulating expression of this gene. LINKED ARTICLES: This article is part of a themed section on Cannabinoids. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.167.issue-8.
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22924606      PMCID: PMC3525862          DOI: 10.1111/j.1476-5381.2012.02175.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  87 in total

1.  Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.

Authors:  Cristina Blázquez; Anna Chiarlone; Onintza Sagredo; Tania Aguado; M Ruth Pazos; Eva Resel; Javier Palazuelos; Boris Julien; María Salazar; Christine Börner; Cristina Benito; Carolina Carrasco; María Diez-Zaera; Paola Paoletti; Miguel Díaz-Hernández; Carolina Ruiz; Michael Sendtner; José J Lucas; Justo G de Yébenes; Giovanni Marsicano; Krisztina Monory; Beat Lutz; Julián Romero; Jordi Alberch; Silvia Ginés; Jürgen Kraus; Javier Fernández-Ruiz; Ismael Galve-Roperh; Manuel Guzmán
Journal:  Brain       Date:  2010-10-07       Impact factor: 13.501

Review 2.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

3.  Altered dendritic distribution of dopamine D2 receptors and reduction in mitochondrial number in parvalbumin-containing interneurons in the medial prefrontal cortex of cannabinoid-1 (CB1) receptor knockout mice.

Authors:  Megan L Fitzgerald; June Chan; Kenneth Mackie; Carl R Lupica; Virginia M Pickel
Journal:  J Comp Neurol       Date:  2012-12-01       Impact factor: 3.215

4.  PAX3-FOXO1 induces cannabinoid receptor 1 to enhance cell invasion and metastasis.

Authors:  Amy D Marshall; Irina Lagutina; Gerard C Grosveld
Journal:  Cancer Res       Date:  2011-10-28       Impact factor: 12.701

5.  Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex.

Authors:  S M Eggan; D S Melchitzky; S R Sesack; K N Fish; D A Lewis
Journal:  Neuroscience       Date:  2010-06-11       Impact factor: 3.590

6.  Methamphetamine neurotoxicity increases brain expression and alters behavioral functions of CB₁ cannabinoid receptors.

Authors:  Marco Bortolato; Roberto Frau; Valentina Bini; William Luesu; Roberta Loriga; Maria Collu; Gian Luigi Gessa; M Grazia Ennas; M Paola Castelli
Journal:  J Psychiatr Res       Date:  2010-04-07       Impact factor: 4.791

7.  Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor.

Authors:  D Shire; B Calandra; M Rinaldi-Carmona; D Oustric; B Pessègue; O Bonnin-Cabanne; G Le Fur; D Caput; P Ferrara
Journal:  Biochim Biophys Acta       Date:  1996-06-07

8.  Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice.

Authors:  Elizabeth A McCaw; Haibei Hu; Geraldine T Gomez; Andrea L O Hebb; Melanie E M Kelly; Eileen M Denovan-Wright
Journal:  Eur J Biochem       Date:  2004-12

9.  Identification and characterisation of a novel splice variant of the human CB1 receptor.

Authors:  Erik Ryberg; Huy Khang Vu; Niklas Larsson; Thierry Groblewski; Stephan Hjorth; Thomas Elebring; Sven Sjögren; Peter J Greasley
Journal:  FEBS Lett       Date:  2005-01-03       Impact factor: 4.124

10.  Receptor heteromerization expands the repertoire of cannabinoid signaling in rodent neurons.

Authors:  Raphael Rozenfeld; Ittai Bushlin; Ivone Gomes; Nikos Tzavaras; Achla Gupta; Susana Neves; Lorenzo Battini; G Luca Gusella; Alexander Lachmann; Avi Ma'ayan; Robert D Blitzer; Lakshmi A Devi
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

View more
  20 in total

1.  Central adiponectin induces trabecular bone mass partly through epigenetic downregulation of cannabinoid receptor CB1.

Authors:  Hua Jiang; Yuwei Wu; Paloma Valverde; Dana Murray; Jin Tang; Qi Yao; Qianqian Han; Jin Zhang; Lan Zhang; Lei Sui; Yin Tang; Qisheng Tu; Jake Chen
Journal:  J Cell Physiol       Date:  2018-11-27       Impact factor: 6.384

2.  2012 cannabinoid themed section.

Authors:  Stephen P H Alexander
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

3.  Targeted inhibition of the type 2 cannabinoid receptor is a novel approach to reduce renal fibrosis.

Authors:  Lili Zhou; Shan Zhou; Peng Yang; Yuan Tian; Zhiwei Feng; Xiang-Qun Xie; Youhua Liu
Journal:  Kidney Int       Date:  2018-08-06       Impact factor: 10.612

4.  Histone methyltransferase G9a diminishes expression of cannabinoid CB1 receptors in primary sensory neurons in neuropathic pain.

Authors:  Yi Luo; Jixiang Zhang; Lin Chen; Shao-Rui Chen; Hong Chen; Guangfen Zhang; Hui-Lin Pan
Journal:  J Biol Chem       Date:  2020-02-04       Impact factor: 5.157

Review 5.  Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.

Authors:  Daniela Navarro; Ani Gasparyan; Francisco Navarrete; Abraham B Torregrosa; Gabriel Rubio; Marta Marín-Mayor; Gabriela B Acosta; Maria Salud Garcia-Gutiérrez; Jorge Manzanares
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

Review 6.  Inflammation and Nitro-oxidative Stress as Drivers of Endocannabinoid System Aberrations in Mood Disorders and Schizophrenia.

Authors:  Gerwyn Morris; Luba Sominsky; Kenneth R Walder; Michael Berk; Wolfgang Marx; André F Carvalho; Chiara C Bortolasci; Michael Maes; Basant K Puri
Journal:  Mol Neurobiol       Date:  2022-03-26       Impact factor: 5.682

7.  Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.

Authors:  Robert B Laprairie; Amina M Bagher; Melanie E M Kelly; Denis J Dupré; Eileen M Denovan-Wright
Journal:  J Biol Chem       Date:  2014-07-18       Impact factor: 5.157

8.  Spontaneous involution of pediatric low-grade gliomas: high expression of cannabinoid receptor 1 (CNR1) at the time of diagnosis may indicate involvement of the endocannabinoid system.

Authors:  Simone Treiger Sredni; Chiang-Ching Huang; Mario Suzuki; Tatiana Pundy; Pauline Chou; Tadanori Tomita
Journal:  Childs Nerv Syst       Date:  2016-09-09       Impact factor: 1.475

9.  Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels.

Authors:  Francesca Rossi; Silverio Perrotta; Giulia Bellini; Livio Luongo; Chiara Tortora; Dario Siniscalco; Matteo Francese; Marco Torella; Bruno Nobili; Vincenzo Di Marzo; Sabatino Maione
Journal:  Haematologica       Date:  2014-09-12       Impact factor: 9.941

10.  Cannabinoid receptor CNR1 expression and DNA methylation in human prefrontal cortex, hippocampus and caudate in brain development and schizophrenia.

Authors:  Ran Tao; Chao Li; Andrew E Jaffe; Joo Heon Shin; Amy Deep-Soboslay; Rae'e Yamin; Daniel R Weinberger; Thomas M Hyde; Joel E Kleinman
Journal:  Transl Psychiatry       Date:  2020-05-19       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.